Evidence map›Paper›PMID 17634183›Full record

Trial reportArchives of disease in childhood2008

Daily versus as-needed inhaled corticosteroid for mild persistent asthma (The Helsinki early intervention childhood asthma study).

M Turpeinen, K Nikander, A S Pelkonen, P Syvänen, R Sorva, H Raitio, P Malmberg, K Juntunen-Backman, T Haahtela

Open access · bronzeAbstract readComparative StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Archives of disease in childhood, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 7 pooled it
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 7 syntheses or guidelines pooled it, 103 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Guideline
  8. Trial
  9. Trial
  10. Review
  11. Review
  12. Review
  13. Review
  14. The Global Initiative for Asthma 2019 recommendation for mild asthma - A critique.South African family practice : official journal of the South African Academy of Family Practice/Primary Care · 2020
    Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

M TurpeinenDepartment of Allergy, Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland. markku.t.turpeinen@hus.fi
K Nikander
A S Pelkonen
P Syvänen
R Sorva
H Raitio
P Malmberg
K Juntunen-Backman
T Haahtela
Helsinki University Hospital · FIAllergy and Asthma Federation · FIAstraZeneca (Sweden) · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo compare the effect of inhaled budesonide given daily or as-needed on mild persistent childhood asthma. Patients, design and

interventions176 children aged 5-10 years with newly detected asthma were randomly assigned to three treatment groups: (1) continuous budesonide (400 microg twice daily for 1 month, 200 microg twice daily for months 2-6, 100 microg twice daily for months 7-18); (2) budesonide, identical treatment to group 1 during months 1-6, then budesonide for exacerbations as needed for months 7-18; and (3) disodium cromoglycate (DSCG) 10 mg three times daily for months 1-18. Exacerbations were treated with budesonide 400 microg twice daily for 2 weeks.

main outcome measuresLung function, the number of exacerbations and growth.

resultsCompared with DSCG the initial regular budesonide treatment resulted in a significantly improved lung function, fewer exacerbations and a small but significant decline in growth velocity. After 18 months, however, the lung function improvements did not differ between the groups. During months 7-18, patients receiving continuous budesonide treatment had significantly fewer exacerbations (mean 0.97), compared with 1.69 in group 2 and 1.58 in group 3. The number of asthma-free days did not differ between regular and intermittent budesonide treatment. Growth velocity was normalised during continuous low-dose budesonide and budesonide therapy given as needed. The latter was associated with catch-up growth.

conclusionsRegular use of budesonide afforded better asthma control but had a more systemic effect than did use of budesonide as needed. The dose of ICS could be reduced as soon as asthma is controlled. Some children do not seem to need continuous ICS treatment.

Indexed as

Administration, InhalationAdrenal Cortex HormonesAnti-Asthmatic AgentsAsthmaBudesonideChildChild, PreschoolCromolyn SodiumDouble-Blind MethodDrug Administration ScheduleFemaleGrowthHumansLungMaleRespiratory Function TestsAdrenal Cortex HormonesAnti-Asthmatic AgentsBudesonideCromolyn Sodium

Identifiers

PMID17634183
PMCPMC2532957
OpenAlexW2103408661

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.